Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.

"Conflict of interest The CAPTURE study was supported by Bayer AG and Merck Sharp and Dohme. Editorial support was provided by Adelphi Communications Ltd, supported by Bayer AG. HG reports personal fees from Actelion, AstraZeneca, Bayer AG, GSK, Janssen Cilag, Lilly, Pfizer, and United Therapeutics. J-LV reports grants from Actelion, Bayer AG, GSK, Lilly, and Merck, and holding the Actelion Chair for research in PH within his institution. NT reports lecture honoraria from Actelion, Bayer Yakuhin, Daiichi-Sankyo, and being a member of an endowed department with Actelion. MH reports board membership for Actelion, Bayer AG, GSK, and Novartis; lecture fees from Actelion, AstraZeneca, Bayer AG, GSK, Lilly, MSD, Novartis, and Pfizer; and personal fees from Actelion, Bayer AG, GSK, Lilly, and Novartis. MO-L has nothing to disclose. LM reports personal fees from Actelion and Bayer AG, and consulting, speaker fees, and research funding from Actelion and Bayer AG. MC reports employment by Bayer AG. KV reports employment by Bayer AG. EG reports grants from Actelion, Bayer AG, GSK, Lilly, and Pfizer; personal fees from Bayer AG, Milteny, Novartis, and United Therapeutics; and non-financial support from Alexion."

"Funding was provided by Bayer AG and Merck Sharp and Dohme. The authors wish to acknowledge the study nurse Sina Heuser for her contribution to the study. Compliance with Ethical Standards: Conflict of interestThe CAPTURE study was supported by Bayer AG and Merck Sharp and Dohme. Editorial support was provided by Adelphi Communications Ltd, supported by Bayer AG. HG reports personal fees from Actelion, AstraZeneca, Bayer AG, GSK, Janssen Cilag, Lilly, Pfizer, and United Therapeutics. J-LV reports grants from Actelion, Bayer AG, GSK, Lilly, and Merck, and holding the Actelion Chair for research in PH within his institution. NT reports lecture honoraria from Actelion, Bayer Yakuhin, Daiichi-Sankyo, and being a member of an endowed department with Actelion. MH reports board membership for Actelion, Bayer AG, GSK, and Novartis; lecture fees from Actelion, AstraZeneca, Bayer AG, GSK, Lilly, MSD, Novartis, and Pfizer; and personal fees from Actelion, Bayer AG, GSK, Lilly, and Novartis. MO-L has nothing to disclose. LM reports personal fees from Actelion and Bayer AG, and consulting, speaker fees, and research funding from Actelion and Bayer AG. MC reports employment by Bayer AG. KV reports employment by Bayer AG. EG reports grants from Actelion, Bayer AG, GSK, Lilly, and Pfizer; personal fees from Bayer AG, Milteny, Novartis, and United Therapeutics; and non-financial support from Alexion.: Ethical ApprovalThe study was carried out within an approved indication in accordance with guidelines and regulations of EMA, FDA and applicable local laws and regulations. ICH-GCP guidelines were followed wherever possible. In all countries where reference to an IEC/IRB is required, documented approval for appropriate IEC/IRB will be obtained for all participating centers prior to study start.: Informed ConsentInformed consent was obtained from all individual participants included in this study."